169 related articles for article (PubMed ID: 26261844)
1. Hydrocodone bitartrate for chronic pain.
Manchikanti L; Atluri S; Kaye AM; Kaye AD
Drugs Today (Barc); 2015 Jul; 51(7):415-27. PubMed ID: 26261844
[TBL] [Abstract][Full Text] [Related]
2. Zohydro approval by food and drug administration: controversial or frightening?
Manchikanti L; Atluri S; Candido KD; Boswell MV; Simopoulos TT; Grider JS; Falco FJ; Hirsch JA
Pain Physician; 2014; 17(4):E437-50. PubMed ID: 25054396
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain.
Bartoli A; Michna E; He E; Wen W
Postgrad Med; 2015 Jan; 127(1):5-12. PubMed ID: 25526227
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain.
Taber L; Lynch SY; He E; Ripa SR
Postgrad Med; 2016 Jan; 128(1):23-33. PubMed ID: 26681111
[TBL] [Abstract][Full Text] [Related]
5. Hysingla® ER, a once-daily, single-entity hydrocodone with abuse-deterrent properties in treating chronic nonmalignant and nonneuropathic pain in patients with osteoarthritis.
Taber L; Baldridge S; He E; Ripa SR
Postgrad Med; 2017 Jan; 129(1):133-139. PubMed ID: 27983881
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic evaluation of hydrocodone/acetaminophen for pain management.
Singla A; Sloan P
J Opioid Manag; 2013; 9(1):71-80. PubMed ID: 23709306
[TBL] [Abstract][Full Text] [Related]
7. Hydrocodone Bitartrate ER (Hysingla
Dhillon S
Clin Drug Investig; 2016 Nov; 36(11):969-980. PubMed ID: 27718163
[TBL] [Abstract][Full Text] [Related]
8. Codeine/acetaminophen and hydrocodone/acetaminophen combination tablets for the management of chronic cancer pain in adults: a 23-day, prospective, double-blind, randomized, parallel-group study.
Rodriguez RF; Castillo JM; Del Pilar Castillo M; Nuñez PD; Rodriguez MF; Restrepo JM; Rodriguez JM; Ortiz Y; Angel AM
Clin Ther; 2007 Apr; 29(4):581-7. PubMed ID: 17617281
[TBL] [Abstract][Full Text] [Related]
9. Analgesic efficacy and tolerability of oxycodone 5 mg/ibuprofen 400 mg compared with those of oxycodone 5 mg/acetaminophen 325 mg and hydrocodone 7.5 mg/acetaminophen 500 mg in patients with moderate to severe postoperative pain: a randomized, double-blind, placebo-controlled, single-dose, parallel-group study in a dental pain model.
Litkowski LJ; Christensen SE; Adamson DN; Van Dyke T; Han SH; Newman KB
Clin Ther; 2005 Apr; 27(4):418-29. PubMed ID: 15922815
[TBL] [Abstract][Full Text] [Related]
10. Combination hydrocodone and ibuprofen versus combination codeine and acetaminophen for the treatment of chronic pain.
Palangio M; Damask MJ; Morris E; Doyle RT; Jiang JG; Landau CJ; de Padova A
Clin Ther; 2000 Jul; 22(7):879-92. PubMed ID: 10945514
[TBL] [Abstract][Full Text] [Related]
11. Analgesic utilization before and after rescheduling of hydrocodone in a large academic level 1 trauma center.
Schultz S; Chamberlain C; Vulcan M; Rana H; Patel B; Alexander JC
J Opioid Manag; 2016; 12(2):119-22. PubMed ID: 27194196
[TBL] [Abstract][Full Text] [Related]
12. A retrospective cohort study of long-term immediate-release hydrocodone/acetaminophen use and acetaminophen dosing above the Food and Drug Administration recommended maximum daily limit among commercially insured individuals in the United States (2008-2013).
DeVeaugh-Geiss A; Kadakia A; Chilcoat H; Alexander L; Coplan P
J Pain; 2015 Jun; 16(6):569-79.e1. PubMed ID: 25827064
[TBL] [Abstract][Full Text] [Related]
13. Hydrocodone extended-release: pharmacodynamics, pharmacokinetics and behavioral pharmacology of a controversy.
Gould HJ; Paul D
Pharmacol Res; 2015 Jan; 91():99-103. PubMed ID: 25301538
[TBL] [Abstract][Full Text] [Related]
14. Hydrocodone: does it have a role in palliative care?
Prommer E
J Opioid Manag; 2010; 6(4):295-9. PubMed ID: 20862909
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain.
Hale ME; Zimmerman TR; Eyal E; Malamut R
J Opioid Manag; 2015; 11(6):507-18. PubMed ID: 26728648
[TBL] [Abstract][Full Text] [Related]
16. Recent developments toward the safer use of opioids, with a focus on hydrocodone.
Covvey JR
Res Social Adm Pharm; 2015; 11(6):901-8. PubMed ID: 25769501
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Quality of Life, Functioning, Disability, and Work/School Productivity Following Treatment with an Extended-Release Hydrocodone Tablet Formulated with Abuse-Deterrence Technology: A 12-month Open-label Study in Patients with Chronic Pain.
Hale ME; Zimmerman TR; Ma Y; Malamut R
Pain Pract; 2017 Feb; 17(2):229-238. PubMed ID: 26857424
[TBL] [Abstract][Full Text] [Related]
18. Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic pain.
Hale ME; Zimmerman TR; Ma Y; Malamut R
J Opioid Manag; 2015; 11(5):425-34. PubMed ID: 26535970
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain.
Pergolizzi J; Kowalski M; He E
Pain Med; 2018 May; 19(5):967-977. PubMed ID: 28371835
[TBL] [Abstract][Full Text] [Related]
20. Relative Bioavailability, Intranasal Abuse Potential, and Safety of Benzhydrocodone/Acetaminophen Compared with Hydrocodone Bitartrate/Acetaminophen in Recreational Drug Abusers.
Guenther SM; Mickle TC; Barrett AC; Roupe KA; Zhou J; Lam V
Pain Med; 2018 May; 19(5):955-966. PubMed ID: 29025138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
